Skip to main content
Erschienen in: Familial Cancer 4/2009

01.12.2009

Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting

verfasst von: Debra Morgan, Heather Sylvester, F. Lee Lucas, Susan Miesfeldt

Erschienen in: Familial Cancer | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

The context is that there are limited data regarding the management of women at risk for hereditary breast and ovarian cancer (HBOC) after genetic counseling in the community setting. The objective of the study is to examine the cancer screening and prevention behaviors among women with diverse risk factors for HBOC, counseled through a non-academic genetic counseling service. This study was designed as a retrospective telephone survey. A community/private-hospital based cancer genetic counseling service was setting. The patients studied were women, at least 21 years of age, who had undergone cancer genetic counseling with: (1) a ≥10% predicted likelihood of carrying a BRCA1/2 mutation; (2) a documented BRCA1/2 mutation. A 121-item telephone survey was intervened. Main outcome measures are (1) reason for referral, (2) genetic testing/results, and (3) screening and prevention behaviors. Sixty-nine women participated (31% response rate). Forty-nine (71%) respondents had a history of breast cancer. Forty-three women (62%) reported undergoing BRCA1/2 testing, of these, seven (16%) had a deleterious mutation; 32 (74%) received negative results and four (9%) had “inconclusive” findings. Among the seven with documented mutations; five had a personal history of breast cancer; none had a history of ovarian cancer; all had undergone bilateral salpingo-oophorectomy (BSO), while five (71%) had undergone bilateral mastectomy. Among those 62 respondents without a documented mutation, pretest likelihood of a BRCA1/2 mutation (based on established models) was as follows: 10–29% likelihood in 38 (61%); 30–59% likelihood in 16 (26%); and ≥60% likelihood in eight (13%). Of these, 16 (26%) had undergone bilateral mastectomy for treatment and/or risk-reduction while 20 (32%) had undergone BSO for risk-reduction or for “other reasons”. Almost all who had not undergone bilateral mastectomy were presenting for regular mammograms; fewer were undergoing regular breast MRI imaging. For those who had not undergone risk-reducing BSO; few were having CA-125 levels or transvaginal ultrasounds. Among those studied, the majority underwent genetic testing. A significant percentage elected to undergo risk-reducing mastectomy and BSO. Although prophylactic surgical decisions appeared to be largely influenced by BRCA mutation status, a number of women in the lower risk categories had undergone these procedures.
Literatur
3.
Zurück zum Zitat Ford D, Easton DF et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62(3):676–689. doi:10.1086/301749 CrossRefPubMed Ford D, Easton DF et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62(3):676–689. doi:10.​1086/​301749 CrossRefPubMed
4.
Zurück zum Zitat Antoniou A, Pharoah PD et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130. doi:10.1086/375033 CrossRefPubMed Antoniou A, Pharoah PD et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130. doi:10.​1086/​375033 CrossRefPubMed
5.
Zurück zum Zitat Easton DF, Steele L et al (1997) Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12–13. Am J Hum Genet 61(1):120–128. doi:10.1086/513891 CrossRefPubMed Easton DF, Steele L et al (1997) Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12–13. Am J Hum Genet 61(1):120–128. doi:10.​1086/​513891 CrossRefPubMed
8.
Zurück zum Zitat Brose MS, Rebbeck TR et al (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94(18):1365–1372PubMed Brose MS, Rebbeck TR et al (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94(18):1365–1372PubMed
9.
Zurück zum Zitat Thompson D, Easton DF (2002) Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94(18):1358–1365PubMed Thompson D, Easton DF (2002) Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94(18):1358–1365PubMed
11.
Zurück zum Zitat U.S. Preventive Services Task Force (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 143(5):355–361 U.S. Preventive Services Task Force (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 143(5):355–361
12.
Zurück zum Zitat Kauff ND, Domchek SM et al (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26(8):1331–1337. doi:10.1200/JCO.2007.13.9626 CrossRefPubMed Kauff ND, Domchek SM et al (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26(8):1331–1337. doi:10.​1200/​JCO.​2007.​13.​9626 CrossRefPubMed
18.
Zurück zum Zitat Wideroff L, Freedman AN et al (2003) Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev 12(4):295–303PubMed Wideroff L, Freedman AN et al (2003) Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev 12(4):295–303PubMed
21.
Zurück zum Zitat Botkin JR, Smith KR et al (2003) Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet 118(3):201–209. doi:10.1002/ajmg.a.10102 CrossRef Botkin JR, Smith KR et al (2003) Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet 118(3):201–209. doi:10.​1002/​ajmg.​a.​10102 CrossRef
22.
Zurück zum Zitat Meijers-Heijboer H, Brekelmans CT et al (2003) Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol 21(9):1675–1681. doi:10.1200/JCO.2003.09.052 CrossRefPubMed Meijers-Heijboer H, Brekelmans CT et al (2003) Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol 21(9):1675–1681. doi:10.​1200/​JCO.​2003.​09.​052 CrossRefPubMed
23.
Zurück zum Zitat Peshkin BN, Schwartz MD et al (2002) Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev 11(10 Pt 1):1115–1118PubMed Peshkin BN, Schwartz MD et al (2002) Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev 11(10 Pt 1):1115–1118PubMed
25.
26.
Zurück zum Zitat Metcalfe KA, Jan Lubinski J et al (2008) Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the hereditary breast cancer clinical study group. J Clin Oncol 26(7):1093–1097. doi:10.1200/JCO.2007.12.6078 CrossRefPubMed Metcalfe KA, Jan Lubinski J et al (2008) Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the hereditary breast cancer clinical study group. J Clin Oncol 26(7):1093–1097. doi:10.​1200/​JCO.​2007.​12.​6078 CrossRefPubMed
29.
Zurück zum Zitat Burke W, Daly M, Garber J et al (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277(12):997–1003. doi:10.1001/jama.277.12.997 CrossRefPubMed Burke W, Daly M, Garber J et al (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277(12):997–1003. doi:10.​1001/​jama.​277.​12.​997 CrossRefPubMed
30.
Zurück zum Zitat NCCN Breast Cancer Panel (2000) NCCN practice guidelines for genetics/familial high-risk screening. Breast, Version 1 NCCN Breast Cancer Panel (2000) NCCN practice guidelines for genetics/familial high-risk screening. Breast, Version 1
35.
Zurück zum Zitat Hartmann LC, Sellers TA et al (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93(21):1633–1637PubMedCrossRef Hartmann LC, Sellers TA et al (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93(21):1633–1637PubMedCrossRef
37.
Zurück zum Zitat King MC, Wieand S et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286(18):2251–2256. doi:10.1001/jama.286.18.2251 CrossRefPubMed King MC, Wieand S et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286(18):2251–2256. doi:10.​1001/​jama.​286.​18.​2251 CrossRefPubMed
39.
41.
42.
Zurück zum Zitat Leach MO, Boggis CR et al (2005) Screening with magnetic resonance imaging and mammography in a UK population at high familial risk of breast cancer : a prospective multicentre cohort study (MARIBS). Lancet 365(9473):1769–1778. doi:10.1016/S0140-6736(05)66481-1 CrossRefPubMed Leach MO, Boggis CR et al (2005) Screening with magnetic resonance imaging and mammography in a UK population at high familial risk of breast cancer : a prospective multicentre cohort study (MARIBS). Lancet 365(9473):1769–1778. doi:10.​1016/​S0140-6736(05)66481-1 CrossRefPubMed
44.
Zurück zum Zitat Saslow D et al (2007) American cancer society guidelines breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89CrossRefPubMed Saslow D et al (2007) American cancer society guidelines breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89CrossRefPubMed
Metadaten
Titel
Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting
verfasst von
Debra Morgan
Heather Sylvester
F. Lee Lucas
Susan Miesfeldt
Publikationsdatum
01.12.2009
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 4/2009
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-009-9242-z

Weitere Artikel der Ausgabe 4/2009

Familial Cancer 4/2009 Zur Ausgabe

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.